Advances in treating the ischaemic diabetic foot

Current Vascular Pharmacology

Volumn 6, Issue 1, 2008, Pages 23-28

  Papanas, Nikolaos ^a   Maltezos, Efstratios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Angiogenesis; Diabetic foot; Ischaemia; Peripheral arterial disease

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DALTEPARIN; ILOPROST; KETANSERIN; PLACEBO; RECOMBINANT FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ANTIANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BYPASS SURGERY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETIC FOOT; DRUG SAFETY; FOOT ULCER; HUMAN; INFECTION; INTERMITTENT CLAUDICATION; LIMB BLOOD FLOW; MONONUCLEAR CELL; MONONUCLEAR CELL TRANSPLANTATION; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL EDEMA; PERIPHERAL ISCHEMIA; PERIPHERAL NEUROPATHY; PROTEINURIA; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; ULCER HEALING; UNSPECIFIED SIDE EFFECT; ANGIOGENESIS; ANIMAL; DIABETIC ANGIOPATHY; DRUG EFFECT; PHYSIOLOGY; STEM CELL TRANSPLANTATION;

ANIMALS; DIABETIC ANGIOPATHIES; DIABETIC FOOT; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELL TRANSPLANTATION;

EID: 43249087827     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108783331330     Document Type: Review

References (60)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
2. Colagiuri S, Borch-Johnsen K, Glümer C, Vistisen D. There really is an epidemic of type 2 diabetes. Diabetologia 2005; 48: 1459-63.
3. Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-53.
4. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 366: 1719-24.
5. Reiber GE, Ledoux WR. Epidemiology of diabetic foot ulcers and complications: evidence for prevention. In: Williams R, Herman W, Kinmoth AL, Wareham NJ (Eds), The evidence basis for diabetes care. Chichester, Wiley 2002; 641-65.
6. Edmonds M. The diabetic foot, 2003. Diabetes Metab Res Rev 2004; 20: Suppl 1: S9-S12.
7. Papanas N, Maltezos E, Edmonds M. St Vincent declaration after 15 years or who cleft the devil's foot? VASA 2006; 35: 3-4.
8. Bakker K, Foster AVM, van Houtoum WH, Riley P (Eds), International Diabetes Federation and International Working Group of the Diabetic Foot Time to act. The Netherlands, 2005.
9. Jeffcoate WJ, van Houtum WH. Amputation as a marker of the quality of foot care in diabetes. Diabetologia 2004; 47: 2051-8.
10. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001; 24: 1433-1437.
11. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004; 351: 48-55.
12. Edmonds ME, Foster AVM, Sanders LJ. Stage 3: the ulcerated foot. In: Edmonds ME, Foster AVM, Sanders LJ, A Practical Manual of diabetic footcare. Oxford, Blackwell 2004; 62-101.
13. Edmonds ME, Foster AVM, Sanders LJ. Stage 4: the infected foot. In: Edmonds ME, Foster AVM, Sanders LJ, A Practical Manual of diabetic footcare. Oxford, Blackwell 2004; 102-140.
14. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 2006; 117(7 Suppl): 212S-238S.
15. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50: 18-25.
16. Sumpio BE, Lee T, Blume PA. Vascular evaluation and arterial reconstruction of the diabetic foot. Clin Podiatr Med Surg 2003; 20: 689-708.
17. Rosenblatt MS, Quist WC, Sidawy AN, Paniszyn CC, LoGerfo FW. Results of vein graft reconstruction of the lower extremity in diabetic and nondiabetic patients. Surg Gynecol Obstet 1990; 171: 331-5.
18. Faglia E, Mantero M, Caminiti M, Caravaggi C, De Giglio R, Pritelli C, et al. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J Intern Med 2002; 252: 225-32.
19. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M, et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg 2005; 29: 620-7.
20. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M, Campbell DR, et al. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. J Vasc Surg 2003; 37: 307-15.
21. Sigala F, Georgopoulos S, Langer S, Baunach C, Papalambros E, Sigalas K, et al. Outcome of infrainguinal revascularization for critical limb ischemia in diabetics with end stage renal disease. VASA 2006; 35: 15-20.
22. Faglia E, Clerici G, Clerissi J, Gabrielli L, Losa S, Mantero M, et al. Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg 2006; 32: 484-90.
23. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295: 547-53.
24. Ouriel K. Peripheral arterial disease. Lancet 2001; 358: 1257-64.
25. Criqui MH. Peripheral vascular disease - epidemiological aspects. Vasc Med 2001; 6: 3-7.
26. Morishita R. Perspective in progress of cardiovascular gene therapy. J Pharmacol Sci 2004; 95: 1-8.
27. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-63.
28. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99: 111-20.
29. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005; 112: 1813-24.
30. Tarzami ST, Singh JP. Pharmacological revascularisation in coronary and peripheral vascular disease. Expert Opin Invest Drugs 2004; 13: 1319-26.
31. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Reviews 2004; 25: 581-611.
32. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-8.
33. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-33.
34. Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003; 114: 85-92.
35. Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, Pak R, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 2002; 90: 512-6.
36. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359: 2053-8.
37. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 2000; 36: 1239-44.
38. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-6.
39. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, et al. Therapeutic angiogenesis induced by Human Hepatocyte Growth Factor gene in rat diabetic hind limb ischemia model: Molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104: 2344-50.
40. Salis Mb, Graiani G, Desortes E, Caldwell RB, Madeddu P, Emanueli C. Nerve growth factor supplementation reverses the impairment, induced by Type 1 diabetes, of hind limb post-ischaemic recovery in mice. Diabetologia 2004; 47: 1055-63.
41. Generini S, Tuveri MA, Matucci CM, Mastinu F, Manni L, Aloe L. Topical application of Nerve Growth Factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes 2004; 112: 542-4.
42. Cooper LT Jr, Hiatt WR, Creager MA, Regensteiner JG, Casscells W, Isner JM, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001; 6: 235-9.
43. Aiello LP, Wong J-S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 2000; 58(Suppl 77): S113-S119.
44. Badiavas EV, Falanga V. Treatment of chronic wounds with bone-marrow derived cells. Arch Dermatol 2003; 139: 510-6.
45. Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A, et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells 2004; 22: 812-22.
46. Bartsch T, Brehm M, Falke T, Kogler G, Wernet P, Strauer BE. Rapid healing of a therapy-refractory diabetic foot after transplantation of autologous bone marrow stem cells. Med Klin 2005; 100: 676-80.
47. Bartsch T, Falke T, Brehm M, Zeus T, Kogler G, Wernet P. et al. Intra-arterial and intramuscular transplantation of adult, autologous bone marrow stem cells. Novel treatment for therapy-refractory peripheral arterial occlusive disease. Dtsch Med Wochenschr 2006; 131: 79-83.
48. Bartsch T, Falke T, Brehm M, Zeus T, Kogler G, Wernet P, et al. Transplantation of autologous adult bone marrow stem cells in patients with severe peripheral arterial occlusion disease. Med Klin 2006; 101 (Suppl 1): 195-7.
49. Yang XF, Wu YX, Wang HM, Xu YF, Lu X, Zhang YB, et al. Autologous peripheral blood stem cells transplantation in treatment of 62 cases of lower extremity ischemic disorder. Zhonghua Nei Ke Za Zhi 2005; 44: 95-8.
50. Apelqvist J, Castenfors J, Larsson J, Stenstrom A, Persson G. Ketanserin in the treatment of diabetic foot ulcer with severe peripheral vascular disease. Int Angiol 1990; 9: 120-4.
51. Martinez-de Jesus FR, Morales-Guzman M, Castaneda M, Perez-Morales A, Garcia-Alonso J, Mendiola-Segura I. Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers. Arch Med Res 1997; 28: 95-9.
52. Quatresooz P, Kharfi M, Paquet P, Vroome V, Cauwenbergh G, Pierard GE. Healing effect of ketanserin on chronic leg ulcers in patients with diabetes. J Eur Acad Dermatol Venereol 2006; 20: 277-81.
53. Jorneskog G, Brismar K, Fagrell B. Low molecular weight heparin seems to improve local capillary circulation and healing of chronic foot ulcers in diabetic patients. VASA 1993; 22: 137-42.
54. Kalani M, Apelqvist J, Blomback M, Brismar K, Eliasson B, Eriksson JW, et al.1 Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2575-80.
55. Brock FE, Abri O, Baitsch G, Bechara G, Beck K, Corovic D, et al. Iloprost in the treatment of ischaemic tissue lesions in diabetic patients. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweiz Med Wochenschr 1990; 120: 1477-82.
56. Petrova N, Edmonds M. Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs 2006; 11: 709-724.
57. Freedman SB. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol 2002; 13: 653-61.
58. Papanas N, Maltezos E, Edmonds M. The diabetic foot: a plea for the elementary? Acta Diabetol 2006; 43: 152-3.
59. van Houtum WH, Rauwerda JA, Ruwaard D, Schaper NC, Bakker K. Reduction in diabetes-related lower-extremity amputations in The Netherlands: 1991-2000. Diabetes Care 2004; 27: 1042-6.
60. El Sakka K, Fassiadis N, Gambhir RP, Halawa M, Zayed H, Doxford M, et al. An integrated care pathway to save the critically ischaemic diabetic foot. Int J Clin Pract 2006; 60: 667-9.